The present invention is directed to pharmaceutical compositions comprisingan antibody specif ic for CSl (CD2 subset 1 ), a member of the CD2 family of cell surfaceglycoproteins, which is highly expressed in myeloma cells, in combination withone or more therapeutic agents. Methods of treating multiple myeloma using saidcompositions are also the obj ect of the present invention.